Acquisition by Necina Roman of 112100 shares of Hookipa Pharma subject to Rule 16b-3

HOOK Stock  USD 1.90  0.12  5.94%   
About 53% of Hookipa Pharma's institutional investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Hookipa Pharma suggests that some traders are interested. Hookipa Pharma's investing sentiment shows overall attitude of investors towards Hookipa Pharma.
  
Filed transaction by Hookipa Pharma Inc officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Hookipa insider trading alert for grant of stock option right to buy by Necina Roman, Chief Development Officer, on 18th of April 2023. This event was filed by Hookipa Pharma Inc with SEC on 2023-04-18. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Hookipa Pharma's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Hookipa Pharma's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Hookipa Pharma Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Hookipa Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Hookipa Pharma Fundamental Analysis

We analyze Hookipa Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hookipa Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hookipa Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Price To Earnings To Growth

Price To Earnings To Growth Comparative Analysis

Hookipa Pharma is currently under evaluation in price to earnings to growth category among its peers. PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

Hookipa Pharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Hookipa Pharma stock to make a market-neutral strategy. Peer analysis of Hookipa Pharma could also be used in its relative valuation, which is a method of valuing Hookipa Pharma by comparing valuation metrics with similar companies.

Peers

Hookipa Pharma Related Equities

MREOMereo BioPharma   12.39   
0%
100.0%
DAWNDay One   0.16   
1.0%
0%
TERNTerns Pharmaceuticals   1.02   
8.0%
0%
AMLXAmylyx Pharmaceuticals   1.72   
13.0%
0%
PDSBPDS Biotechnology   1.80   
14.0%
0%
ELDNEledon Pharmaceuticals   2.06   
16.0%
0%
INZYInozyme Pharma   2.66   
21.0%
0%
ABOSAcumen Pharmaceuticals   3.24   
26.0%
0%
XFORX4 Pharmaceuticals   4.92   
39.0%
0%
When determining whether Hookipa Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Hookipa Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Hookipa Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Hookipa Pharma Stock:
Check out Hookipa Pharma Hype Analysis, Hookipa Pharma Correlation and Hookipa Pharma Performance.
For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.67)
Revenue Per Share
4.403
Quarterly Revenue Growth
(0.52)
Return On Assets
(0.20)
Return On Equity
(0.49)
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.